National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (Cth)

PB 125 of 2023

National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 30 November 2023

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Minimum Stockholding) Determination 2023   2

1  Name

(1)  This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023.

(2)  This instrument may also be cited as PB 125 of 2023.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 December 2023	1 December 2023

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Minimum Stockholding) Determination 2023

1  Schedule 1

After:

Acarbose Tablet 50 mg Oral GLYBOSAY 2 months stock by reference to usual demand

insert:

Aciclovir Tablet 200 mg Oral GenRx Aciclovir between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand

2  Schedule 1

Omit:

Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol Oral Alendronate Plus D3 Sandoz between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

3  Schedule 1

Omit:

Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol Oral Alendronate Plus D3 Sandoz between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

4  Schedule 1

Omit:

Amino acid formula with vitamins and minerals without phenylalanine Oral gel 85 g, 30 (PKU squeezie) Oral PKU squeezie after 30 November 2023—6 months stock by reference to usual PBS demand

substitute:

Amino acid formula with vitamins and minerals without phenylalanine Oral gel 85 g, 30 (PKU squeezie) Oral PKU squeezie 0 months stock by reference to usual PBS demand

5  Schedule 1

Omit:

Amisulpride Tablet 400 mg Oral Amisulpride 400 Winthrop between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

6  Schedule 1

After:

Amitriptyline Tablet containing amitriptyline hydrochloride 50 mg Oral ENTRIP (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand; (b) after 31 December 2023—4.5 months stock by reference to usual demand

insert:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Amlodipine Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 500/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 875/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

7  Schedule 1

Omit:

Anastrozole Tablet 1 mg Oral Anastrozole FBM between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

8  Schedule 1

Omit:

Aripiprazole Tablet 10 mg Oral Aripiprazole generichealth between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

9  Schedule 1

Omit:

Aripiprazole Tablet 15 mg Ora Aripiprazole generichealth between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

10  Schedule 1

Omit:

Aripiprazole Tablet 20 mg Oral Aripiprazole generichealth between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

11  Schedule 1

After:

Aripiprazole Tablet 30 mg Oral APO‑Aripiprazole 3 months stock by reference to usual demand

insert:

Aripiprazole Tablet 30 mg Oral Aripiprazole generichealth between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

12  Schedule 1

After:

Atenolol Tablet 50 mg Oral APX‑Atenolol 4 months stock by reference to usual demand

insert:

Atenolol Tablet 50 mg Oral Atenolol Amneal between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

13  Schedule 1

Omit:

Betamethasone	Cream 500 micrograms (as dipropionate) per g, 15 g	Application	Diprosone	between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand
Betamethasone	Cream 500 micrograms (as dipropionate) per g, 15 g	Application	Eleuphrat	between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand
Betamethasone	Ointment 500 micrograms (as dipropionate) per g, 15 g	Application	Diprosone	between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand
Betamethasone	Ointment 500 micrograms (as dipropionate) per g, 15 g	Application	Eleuphrat	between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand

14  Schedule 1

After:

Baclofen Tablet 10 mg Oral APO‑Baclofen 3 months stock by reference to usual demand

insert:

Bleomycin Powder for injection containing bleomycin sulfate 15,000 I.U. Injection CIPLA BLEOMYCIN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

15  Schedule 1

After:

Bosentan Tablet 125 mg (as monohydrate) Oral Bosentan APO 3 months stock by reference to usual demand

insert:

Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Calcitriol	Capsule 0.25 microgram	Oral	Calcitriol AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

16  Schedule 1

Omit:

Carboplatin Solution for I.V. injection 450 mg in 45 mL Injection DBL Carboplatin between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

17  Schedule 1

After:

Cefalexin Capsule 500 mg (as monohydrate) Oral APO‑Cephalexin between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

insert:

Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cefazolin-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Alphapharm	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

18  Schedule 1

After:

Cefepime Powder for injection 1 g (as hydrochloride) Injection Cefepime‑AFT between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Cefepime Powder for injection 2 g (as hydrochloride) Injection Cefepime Alphapharm between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

19  Schedule 1

Omit:

Cefepime Powder for injection 2 g (as hydrochloride) Injection Cefepime‑AFT between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

20  Schedule 1

After:

Cefepime Powder for injection 2 g (as hydrochloride) Injection Cefepime Alphapharm between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

insert:

Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand

21  Schedule 1

Omit:

Chlorpromazine Tablet containing chlorpromazine hydrochloride 10 mg Oral Largactil between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

22  Schedule 1

After:

Ciclosporin Oral liquid 100 mg per mL, 50 mL Oral Neoral 4 months stock by reference to usual PBS demand

insert:

Citalopram	Tablet 10 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 20 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 40 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

23  Schedule 1

After:

Clarithromycin Powder for oral liquid 250 mg per 5 mL, 50 mL Oral Klacid 4 months stock by reference to usual PBS demand

insert:

Clarithromycin Tablet 250 mg Oral Clarithromycin AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

24  Schedule 1

Omit:

Clopidogrel with aspirin Tablet 75 mg (as hydrogen sulfate)‑100 mg Oral CLOPIDOGREL/ASPIRIN AN 75/100 between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand

25  Schedule 1

After:

Cyproterone Tablet containing cyproterone acetate 100 mg Oral APO‑Cyproterone between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Cyproterone Tablet containing cyproterone acetate 100 mg Oral Cyprone 100 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

26  Schedule 1

After:

Cyproterone Tablet containing cyproterone acetate 50 mg Oral APO‑Cyproterone between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Cyproterone Tablet containing cyproterone acetate 50 mg Oral Cyprone 50 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

27  Schedule 1

Omit:

Desferrioxamine Powder for injection containing desferrioxamine mesilate 2 g Injection DBL Desferrioxamine Mesilate between 1 July 2023 and 31 July 2023—4 months stock by reference to usual demand

28  Schedule 1

After:

Dantrolene Capsule containing dantrolene sodium hemiheptahydrate 25 mg Oral Dantrium 6 months stock by reference to usual PBS demand

insert:

Desvenlafaxine	Tablet (modified release) 100 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Desvenlafaxine	Tablet (modified release) 50 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

29  Schedule 1

After:

Diazepam Oral liquid 10 mg per 10 mL, 100 mL Oral Diazepam Elixir 4 months stock by reference to usual PBS demand

insert:

Diclofenac Tablet (enteric coated) containing diclofenac sodium 25 mg Oral Diclofenac AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

30  Schedule 1

After:

Diclofenac Tablet (enteric coated) containing diclofenac sodium 25 mg Oral Diclofenac Sandoz between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand

insert:

Diclofenac Tablet (enteric coated) containing diclofenac sodium 50 mg Oral Diclofenac AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

31  Schedule 1

After:

Diclofenac Tablet (enteric coated) containing diclofenac sodium 50 mg Oral Fenac (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand; (b) after 31 December 2023—2 months stock by reference to usual demand

insert:

Diltiazem Tablet containing diltiazem hydrochloride 60 mg Oral Diltiazem AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

32  Schedule 1

After:

Domperidone Tablet 10 mg Oral Motilium between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand

insert:

Dosulepin Tablet containing dosulepin hydrochloride 75 mg Oral Dosulepin Viatris 75 6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together

33  Schedule 1

Omit:

Entecavir	Tablet 1 mg (as monohydrate)	Oral	ENTAC	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Entecavir	Tablet 1 mg (as monohydrate)	Oral	Entecavir GH	between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

34  Schedule 1

After:

Ezetimibe with simvastatin Tablet 10 mg‑10 mg Oral EZETORIN 3 months stock by reference to usual demand

insert:

Ezetimibe with simvastatin Tablet 10 mg-10 mg Oral EZEVYT 10/10 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

35  Schedule 1

After:

Ezetimibe with simvastatin Tablet 10 mg‑20 mg Oral EZETORIN 3 months stock by reference to usual demand

insert:

Ezetimibe with simvastatin Tablet 10 mg-20 mg Oral EZEVYT 10/20 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

36  Schedule 1

After:

Ezetimibe with simvastatin Tablet 10 mg‑40 mg Oral EZETORIN 3 months stock by reference to usual demand

insert:

Ezetimibe with simvastatin Tablet 10 mg-40 mg Oral EZEVYT 10/40 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

37  Schedule 1

After:

Ezetimibe with simvastatin Tablet 10 mg‑80 mg Oral EZETORIN 3 months stock by reference to usual demand

insert:

Ezetimibe with simvastatin Tablet 10 mg-80 mg Oral EZEVYT 10/80 between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

38  Schedule 1

After:

Ezetimibe with simvastatin Tablet 10 mg‑80 mg Oral Zeklen 10/80 mg between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand

insert:

Famciclovir	Tablet 125 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 250 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 500 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

39  Schedule 1

After:

Felodipine Tablet 2.5 mg (extended release) Oral Plendil ER 2.5 months stock by reference to usual demand

insert:

Fenofibrate Tablet 145 mg Oral Fenofibrate Viatris 6 months stock by reference to usual demand of both Fenofibrate Viatris and Fenofibrate Mylan added together

40  Schedule 1

Omit:

Filgrastim	Injection 300 micrograms in 0.5 mL single‑use pre‑filled syringe	Injection	Neupogen	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Filgrastim	Injection 300 micrograms in 1 mL	Injection	Neupogen	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Filgrastim	Injection 480 micrograms in 0.5 mL single‑use pre‑filled syringe	Injection	Neupogen	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Filgrastim	Injection 480 micrograms in 1.6 mL	Injection	Neupogen	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

41  Schedule 1

Omit:

Flucloxacillin	Powder for injection 1 g (as sodium monohydrate)	Injection	Flucil	between 1 July 2023 and 30 November 2023—4 months stock by reference to usual demand
Flucloxacillin	Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL	Oral	Flucil	between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand
Flucloxacillin	Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL	Oral	Flucil	between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand

42  Schedule 1

Omit:

Fluorouracil	Injection 2500 mg in 50 mL	Injection	DBL Fluorouracil Injection BP	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Fluoxetine	Capsule 20 mg (as hydrochloride)	Oral	Blooms the Chemist Fluoxetine	between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand

43  Schedule 1

After:

Furosemide Oral solution 10 mg per mL, 30 mL Oral Lasix 4 months stock by reference to usual PBS demand

insert:

Furosemide Tablet 20 mg Oral FUROSEMIDE AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

44  Schedule 1

After:

Furosemide Tablet 20 mg Oral Urex‑M between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Furosemide Tablet 40 mg Oral FUROSEMIDE AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

45  Schedule 1

After:

Gabapentin Capsule 400 mg Oral GAPENTIN 3 months stock by reference to usual demand

insert:

Gabapentin Tablet 600 mg Oral Gabapentin AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

46  Schedule 1

After:

Gemfibrozil Tablet 600 mg Oral Lipigem between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand

insert:

Glimepiride Tablet 2 mg Oral Amaryl between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

47  Schedule 1

Omit:

Glimepiride Tablet 4 mg Oral Amaryl between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand

48  Schedule 1

Omit:

Glucose indicator‑urine Test strips, 50 (Diastix) For External Use Diastix 4 months stock by reference to usual PBS demand

substitute:

Glucose indicator-urine Test strips, 50 (Diastix) For External Use Diastix between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand

49  Schedule 1

Omit:

Hydralazine Tablet containing hydralazine hydrochloride 25 mg Oral Alphapress 25 4 months stock by reference to usual PBS demand

substitute:

Hydralazine Tablet containing hydralazine hydrochloride 25 mg Oral Alphapress 25 between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand

50  Schedule 1

After:

Hydralazine Tablet containing hydralazine hydrochloride 25 mg Oral Alphapress 25 between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand

insert:

Hydrocortisone Tablet 20 mg Oral Hydrocortisone Viatris 20 4 months stock by reference to usual demand of both Hydrocortisone Viatris 20 and Hydrocortisone Mylan 20 added together

51  Schedule 1

Omit:

Imatinib	Capsule 100 mg (as mesilate)	Oral	CIPLA IMATINIB ADULT	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Imatinib	Capsule 100 mg (as mesilate)	Oral	Imatinib GH	between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

52  Schedule 1

Omit:

Imatinib Capsule 400 mg (as mesilate) Oral CIPLA IMATINIB ADULT between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

53  Schedule 1

Omit:

Insulin glargine	Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3	Injection	Toujeo Solostar	between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand
Insulin glargine	Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5	Injection	Toujeo Solostar	between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand

54  Schedule 1

After:

Irbesartan with hydrochlorothiazide Tablet 300 mg‑25 mg Oral AVSARTAN HCT 300/25 between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

insert:

Irbesartan	Tablet 300 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AMNEAL	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Isosorbide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Monodur 60 mg	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 10 mg	Oral	Rocta 10	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 20 mg	Oral	Rocta 20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

55  Schedule 1

Omit:

Labetalol Tablet containing labetalol hydrochloride 200 mg Oral Trandate between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand

56  Schedule 1

Omit:

Letrozole Tablet 2.5 mg Oral Letrozole FBM between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

57  Schedule 1

Omit:

Losartan	Tablet containing losartan potassium 25 mg	Oral	Cozavan	between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand
Macrogol 3350	Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL	Oral	Movicol Liquid	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

58  Schedule 1

After:

Macrogol 3350 Powder for oral solution 510 g Oral OsmoLax between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand

insert:

Meloxicam	Capsule 15 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 15 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

59  Schedule 1

After:

Metformin Tablet containing metformin hydrochloride 1 g Oral APO‑Metformin 1000 between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Metformin Tablet containing metformin hydrochloride 1 g Oral Metformin AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

60  Schedule 1

After:

Metformin Tablet containing metformin hydrochloride 500 mg Oral APO‑Metformin 500 between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Metformin Tablet containing metformin hydrochloride 500 mg Oral Metformin AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

61  Schedule 1

After:

Metformin Tablet containing metformin hydrochloride 850 mg Oral APO‑Metformin 850 between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Chem mart Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Terry White Chemists Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

62  Schedule 1

Omit:

Methotrexate Injection 50 mg in 2 mL vial Injection Methotrexate Accord between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand

63 Schedule 1

After:

Metformin Tablet containing metformin hydrochloride 850 mg Oral Terry White Chemists Metformin between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

insert:

Methotrexate Solution concentrate for I.V. infusion 1000 mg in 10 mL vial Injection Pfizer Australia Pty Ltd between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

64  Schedule 1

After:

Methoxyflurane Liquid for inhalation 999 mg per g, 3 ml (with inhaler) Inhalation by mouth Penthrox 6 months stock by reference to usual PBS demand

insert:

Metoclopramide Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL Injection Maxolon between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

65  Schedule 1

After:

Metoprolol Tablet containing metoprolol tartrate 50 mg Oral Metrol 50 between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

insert:

Mirtazapine Tablet 15 mg (orally disintegrating) Oral Mirtazapine AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

66  Schedule 1

After:

Mirtazapine Tablet 15 mg Oral APO‑Mirtazapine between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Mirtazapine Tablet 30 mg (orally disintegrating) Oral Mirtazapine AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

67  Schedule 1

After:

Mirtazapine Tablet 30 mg Oral APO‑Mirtazapine between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Mirtazapine	Tablet 30 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

68  Schedule 1

After:

Mirtazapine Tablet 45 mg Oral APO‑Mirtazapine between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Mirtazapine	Tablet 45 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mitozantrone	Injection 20 mg (as hydrochloride) in 10 mL	Injection	Onkotrone	between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand
Mitozantrone	Injection 25 mg (as hydrochloride) in 12.5 mL	Injection	Onkotrone	between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand

69  Schedule 1

After:

Moclobemide Tablet 150 mg Oral APO‑Moclobemide between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Moclobemide Tablet 150 mg Oral Moclobemide AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

70  Schedule 1

After:

Moclobemide Tablet 300 mg Oral APO‑Moclobemide between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Moclobemide Tablet 300 mg Oral Moclobemide AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

71  Schedule 1

After:

Morphine Tablet containing morphine sulfate pentahydrate 30 mg Oral Anamorph 3 months stock by reference to usual demand

insert:

Moxonidine Tablet 200 micrograms Oral Moxonidine Viatris 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together

72  Schedule 1

Omit:

Mycophenolic Acid Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL Oral CellCept between 1 July 2023 and 30 September 2023—4 months stock by reference to usual PBS demand

73  Schedule 1

Omit:

Nicorandil Tablets 10 mg, 60 Oral Ikorel between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand

74  Schedule 1

Omit:

Nicorandil Tablets 20 mg, 60 Oral Ikorel between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand

75  Schedule 1

After:

Ondansetron Tablet (orally disintegrating) 4 mg Oral APO‑Ondansetron ODT between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Ondansetron Tablet (orally disintegrating) 4 mg Oral Ondansetron AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

76  Schedule 1

Omit:

Ondansetron Tablet (orally disintegrating) 4 mg Oral Ondansetron ODT Lupin between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

77  Schedule 1

After:

Ondansetron Tablet (orally disintegrating) 8 mg Oral APO‑Ondansetron ODT between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Ondansetron Tablet (orally disintegrating) 8 mg Oral Ondansetron AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

78  Schedule 1

Omit:

Ondansetron Tablet (orally disintegrating) 8 mg Oral Ondansetron ODT Lupin between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

79  Schedule 1

After:

Ondansetron Tablet (orally disintegrating) 8 mg Oral Ondansetron AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

insert:

Ondansetron Tablet 4 mg (as hydrochloride dihydrate) Oral Ondansetron AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

80  Schedule 1

After:

Ondansetron Tablet 4 mg (as hydrochloride dihydrate) Oral Ondansetron APOTEX between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Ondansetron Tablet 8 mg (as hydrochloride dihydrate) Oral Ondansetron AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

81  Schedule 1

Omit:

Oxaliplatin Solution concentrate for I.V. infusion 100 mg in 20 mL Injection DBL Oxaliplatin Concentrate between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

82  Schedule 1

After:

Pantoprazole Tablet (enteric coated) 20 mg (as sodium sesquihydrate) Oral Sozol between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

insert:

Pantoprazole Tablet (enteric coated) 40 mg (as sodium sesquihydrate) Oral Pantoprazole AN between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

83  Schedule 1

Omit:

Paracetamol Tablet 665 mg (modified release) Oral CHEMISTS' OWN OSTEO RELIEF PARACETAMOL between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand

84  Schedule 1

After:

Pantoprazole Tablet (enteric coated) 40 mg (as sodium sesquihydrate) Oral Sozol (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand; (b) after 31 December 2023—5.5 months stock by reference to usual demand

insert:

Paroxetine	Tablet 20 mg (as hydrochloride)	Oral	Paroxetine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Pegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection	Ristempa	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

85  Schedule 1

Omit:

Pemetrexed	Powder for I.V. infusion 100 mg (as disodium)	Injection	Pemetrexed‑AFT	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Pemetrexed	Powder for I.V. infusion 500 mg (as disodium)	Injection	Pemetrexed‑AFT	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

86  Schedule 1

Omit:

Polyvinyl alcohol	Eye drops 14 mg per mL, 15 mL	Application to the Eye	Liquifilm Tears	between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand
Polyvinyl alcohol	Eye drops 14 mg per mL, 15 mL	Application to the Eye	PVA Tears	between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand

87  Schedule 1

After:

Pregabalin Capsule 25 mg Oral LYPRALIN between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Pregabalin Capsule 25 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together

88  Schedule 1

After:

Pregabalin Capsule 300 mg Oral LYPRALIN between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

insert:

Pregabalin Capsule 300 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together

89  Schedule 1

After:

Probenecid Tablet 500 mg Oral Pro‑Cid after 30 November 2023—6 months stock by reference to usual PBS demand

insert:

Quetiapine	Tablet 100 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Quetiapine	Tablet 300 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

90  Schedule 1

After:

Ramipril with felodipine Tablet 2.5 mg‑2.5 mg (modified release) Oral Triasyn 2.5/2.5 4 months stock by reference to usual PBS demand

insert:

Ramipril Capsule 1.25 mg Oral APO-Ramipril between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

91  Schedule 1

Omit:

Ranitidine Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL Oral Zantac Syrup between 1 October 2023 and 30 November 2023—0 months stock by reference to usual PBS demand

92  Schedule 1

After:

Risperidone Tablet 4 mg Oral Rispa between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

insert:

Rizatriptan Tablet (orally disintegrating) 10 mg (as benzoate) Oral Rizatriptan AN ODT between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

93  Schedule 1

Omit:

Roxithromycin Tablet for oral suspension 50 mg Oral Rulide D between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand

94  Schedule 1

After:

Roxithromycin Tablet 300 mg Oral APX‑Roxithromycin (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand; (b) after 31 December 2023—5 months stock by reference to usual demand

insert:

Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Salbutamol AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sertraline	Tablet 100 mg (as hydrochloride)	Oral	Sertraline AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	Sertraline AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sildenafil	Tablet 20 mg (as citrate)	Oral	Sildenafil AN PHT 20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

95  Schedule 1

Omit:

Telmisartan with hydrochlorothiazide Tablet 80 mg‑25 mg Oral Telmisartan HCT GH 80/25 between 1 July 2023 and 30 September 2023—0 months stock by reference to usual demand

96  Schedule 1

Omit:

Tobramycin Injection 80 mg in 2 mL Injection DBL Tobramycin between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

97  Schedule 1

Omit:

Triglycerides - medium chain, formula Oral powder 400 g (Lipistart) Oral Lipistart after 30 November 2023—6 months stock by reference to usual PBS demand

substitute:

Triglycerides—medium chain, formula Oral powder 400 g (Lipistart) Oral Lipistart 0 months stock by reference to usual PBS demand

98  Schedule 1

Omit:

Triglycerides, medium chain Oral liquid 225 mL, 15 (K.Quik) Oral K.Quik after 30 November 2023—6 months stock by reference to usual PBS demand

substitute:

Triglycerides, medium chain Oral liquid 225 mL, 15 (K.Quik) Oral K.Quik 0 months stock by reference to usual PBS demand

99  Schedule 1

After:

Valganciclovir Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL Oral Valcyte 4 months stock by reference to usual PBS demand

insert:

Valganciclovir Tablet 450 mg (as hydrochloride) Oral Valganciclovir Viatris 4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together

100  Schedule 1

Omit:

Vancomycin	Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand

101  Schedule 1

Omit:

Voriconazole Tablet 50 mg Oral Vfend between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand